Clinical trial
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory…
NCT00274651 · Valerio Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00274651 |
|---|---|
| Title | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas |
| Official title | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas |
| Acronym | PXD101-CLN-6 |
| Lead sponsor | Valerio Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | belinostat |
| Enrollment | 53 |
| Start date | Jan 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jan 11, 2006 |
| Last update posted | Jul 28, 2015 |
| Countries | France, Germany, Israel, Thailand, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: